Table 4.
Characteristics of the patients at the time of malignancies' diagnosis for non-AIDS-defining malignancies virus related (NADMs-VR) versus non-AIDS-defining malignancies virus unrelated (NADMs-VUR). Factors statistically associated with NADMs-VUR in bold
| Characteristic | NADM-VR | NADM-VUR | OR | 95% CI | p | |||
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| n | % | n | % | |||||
| Sex | female | 8 | 13.8 | 19 | 26.8 | 1 | - | - |
| male | 50 | 86.2 | 52 | 73.2 | 0.438 | 0.176-1.091 | 0.084 | |
| Age at the malignancies' diagnosis (years) | [20; 30) | 7 | 12.1 | 11 | 15.5 | 1 | - | - |
| [30; 40) | 11 | 19.0 | 11 | 15.5 | 0.636 | 0.18-2.251 | 0.537 | |
| [40; 50) | 21 | 36.2 | 20 | 28.2 | 0.606 | 0.196-1.873 | 0.412 | |
| [50; 60) | 15 | 25.9 | 17 | 23.9 | 0.721 | 0.223-2.335 | 0.768 | |
| [60; 81] | 4 | 06.9 | 12 | 16.9 | 1.909 | 0.436-8.353 | 0.477 | |
| Mode of HIV exposure | bisexual | 2 | 03.4 | 5 | 07.0 | 1 | - | - |
| heterosexual | 11 | 19.0 | 21 | 29.6 | 0.764 | 0.127-4.596 | 1 | |
| IDU | 28 | 48.3 | 27 | 38.0 | 0.386 | 0.069-2.16 | 0.427 | |
| MSM | 17 | 29.3 | 18 | 25.4 | 0.424 | 0.072-2.483 | 0.428 | |
| Duration of HIV-infection at the malignancies' diagnosis (years) | [0; 1) | 10 | 17.2 | 14 | 19.7 | 1 | - | - |
| [1; 5) | 15 | 25.9 | 20 | 28.2 | 0.952 | 0.333-2.7271 | 0.577 | |
| [5; 10) | 14 | 24.1 | 13 | 18.3 | 0.663 | 0.219-2.009 | 1 | |
| [10; 34] | 19 | 32.8 | 24 | 33.8 | 0.902 | 0.329-2.478 | ||
| Opportunistic infections before malignancies' diagnosis | no | 23 | 39.7 | 40 | 56.3 | 1 | - | - |
| yes | 35 | 60.3 | 31 | 43.7 | 0.509 | 0.252-1.031 | 0.077 | |
| Nadir CD4 count (cells/mm3) | [0; 200) | 45 | 77.6 | 48 | 67.6 | 1 | - | - |
| [200; 350) | 11 | 19.0 | 13 | 18.3 | 1.108 | 0.45-2.725 | 1 | |
| [350; 500) | 2 | 03.4 | 4 | 05.6 | 1.875 | 0.327-10.741 | 0.68 | |
| [> 500] | 0 | 0.00 | 6 | 08.5 | Inf | NaN-Inf | 0.03 | |
| Smoking status | no | 12 | 20.7 | 15 | 21.1 | 1 | - | - |
| yes | 46 | 79.3 | 56 | 78.9 | 0.974 | 0.415-2.286 | 1 | |
| Alcohol status | no | 27 | 46.6 | 47 | 66.2 | 1 | - | - |
| yes | 31 | 53.4 | 24 | 33.8 | 0.445 | 0.218-0.907 | 0.032 | |
| Drugs status | no | 29 | 50.0 | 45 | 63.4 | 1 | - | - |
| yes | 29 | 50.0 | 26 | 36.6 | 0.578 | 0.285-1.17 | 0.153 | |
| Hepatitis C status | negative | 27 | 46.6 | 43 | 60.6 | 1 | - | - |
| positive | 31 | 53.4 | 27 | 38.0 | 0.547 | 0.27-1.107 | 0.11 | |
| unknown | 0 | 0.00 | 1 | 01.4 | Inf | NaN-Inf | 1 | |
| Hepatitis B status | negative | 36 | 62.1 | 39 | 54.9 | 1 | - | - |
| positive | 22 | 37.9 | 32 | 45.1 | 1.343 | 0.662-2.723 | 0.475 | |
| unknown | 0 | 0.00 | 0 | 0.00 | NaN | NaN-NaN | 1 | |
| CD4+ count at the malignancies' diagnosis (cells/mm3) | [3; 51) | 8 | 13.8 | 7 | 09.9 | 1 | - | - |
| [51; 501) | 40 | 69.0 | 41 | 57.7 | 1.171 | 0.388-3.533 | 1 | |
| [> 501] | 10 | 17.2 | 23 | 32.4 | 2.629 | 0.748-9.239 | 0.198 | |
| cART before malignancies' diagnosis | no | 25 | 43.1 | 24 | 33.8 | 1 | - | - |
| yes | 33 | 56.9 | 47 | 66.2 | 1.484 | 0.725-3.034 | 0.362 | |
| VL suppression at the malignancies' diagnosis | no | 32 | 55.2 | 37 | 52.1 | 1 | - | - |
| yes | 26 | 44.8 | 34 | 47.9 | 1.131 | 0.564-2.269 | 0.859 | |
| Death during study period | no | 25 | 43.1 | 40 | 56.3 | 1 | - | - |
| yes | 33 | 56.9 | 31 | 43.7 | 0.587 | 0.292-1.182 | 0.158 | |
| Overall survival after malignancies' diagnosis (years) | [0; 1) | 27 | 46.6 | 17 | 23.9 | 1 | - | - |
| [1; 2) | 4 | 06.9 | 16 | 22.5 | 6.353 | 1.816-22.229 | 0.003 | |
| [2; 5) | 11 | 19.0 | 27 | 38.0 | 3.898 | 1.542-9.853 | 0.004 | |
| [5; 10) | 13 | 22.4 | 10 | 14.1 | 1.222 | 0.439-3.401 | 0.795 | |
| [10; 17] | 3 | 05.2 | 1 | 01.4 | 0.529 | 0.051-5.513 | 1 | |
OR – odds ratio; 95% CI – 95% confidence limits; cART – combination antiretroviral therapy; VL – viral load